Summary
DUL Chart
Is Alnylam Pharmaceuticals a Millionaire Maker?
Alnylam has been a big winner for investors since its IPO in 2004. The drugmaker's future looks promising.
American Century Ultra Fund Q3 2025 Contributors/Detractors And Notable Trades
Google's parent company received a relatively benign antitrust ruling that would not force Alphabet to sell its Chrome browser or Android operating system. Chipotle Mexican Grill reported mixed quarterly results as a result of tough year-over-year comparisons and an uncertain macroeconomic environment. We initiated a position in Oracle, which is highly levered to the ongoing artificial intelligence infrastructure build-out.
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Jefferies London Healthcare Conference 2025 Transcript
Alnylam Pharmaceuticals, Inc. ( ALNY ) Jefferies London Healthcare Conference 2025 November 19, 2025 6:30 AM EST Company Participants Yvonne Greenstreet - CEO & Director Tolga Tanguler - Executive VP & Chief Commercial Officer Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Presentation Maurice Raycroft Jefferies LLC, Research Division Hi, everyone. My name is Maurice Raycroft, and I'm one of the Biotech Analysts at Jefferies.
Alnylam Pharmaceuticals Inc. (DUL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Alnylam Pharmaceuticals Inc. ever had a stock split?
Alnylam Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Yvonne L. Greenstreet CEO | XFRA Exchange | US02043Q1076 ISIN |
| US Country | 2,230 Employees | - Last Dividend | - Last Split | 28 May 2004 IPO Date |
Overview
Alnylam Pharmaceuticals, Inc. is a leading biopharmaceutical company that specializes in discovering, developing, and commercializing innovative therapeutics based on ribonucleic acid interference (RNAi). Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam is at the forefront of RNAi technology, employing this revolutionary science to tackle complex diseases at the genetic level. The company's commitment to innovation is underscored by its dynamic pipeline of products and its strategic collaborations with major players in the pharmaceutical industry, such as Regeneron Pharmaceuticals, Inc., Roche, Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. These partnerships aim to expand the potential of RNAi therapy across various diseases, including those affecting the eye, central nervous system (CNS), and more.
Products and Services
- ONPATTRO (patisiran)
Approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults, this product exemplifies Alnylam's commitment to addressing rare diseases with significant unmet needs.
- AMVUTTRA
Also targeting hATTR amyloidosis, AMVUTTRA is specifically approved for treating adults with polyneuropathy, showcasing the company's focused approach on this genetic disorder.
- GIVLAARI (givosiran)
For adults with acute hepatic porphyria (AHP), a rare metabolic disorder, GIVLAARI represents a significant advancement in treatment options, highlighting Alnylam's dedication to tackling challenging hepatic conditions.
- OXLUMO (lumasiran)
This product is designed for the treatment of primary hyperoxaluria type 1 (PH1), a rare genetic disorder, further demonstrating Alnylam's expertise in developing treatments for rare conditions.
- Development Pipeline
- Patisiran - in development for ATTR amyloidosis with cardiomyopathy.
- Cemdisiran - targeted to treat complement-mediated diseases.
- Belcesiran - for the treatment of alpha-1 liver disease.
- Elebsiran - aimed at chronic HBV infection treatment.
- Zilebesiran - under development to treat hypertension, in collaboration with Roche.
- ALN-APP - for Alzheimer's disease and cerebral amyloid angiopathy.
- ALN-HSD - targeted to treat NASH.
- Fitusiran - for the treatment of hemophilia, showcasing Alnylam's expansion into blood disorders.
- Inclisiran - aimed at treating hypercholesterolemia, highlighting Alnylam's foray into cardiovascular diseases.
- Vutrisiran - in phase 3 clinical trial for ATTR amyloidosis, underscoring ongoing commitment to this disease area.
Contact Information
